Versant Venture Management, LLC — 13F Holdings & Portfolio

CIK 1560009 · latest 13F-HR filed 2026-05-05

Versant Venture Management, LLC manages $141.4M in 13F-reported U.S. long-equity assets across 8 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are GLUE (37.00%), IPSC (19.44%), LENZ (17.19%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 1, and trimmed 6.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$141.4M

Long-equity book

Holdings

8

Distinct positions

Period

2026-03-31

Filed 2026-05-05

Q/Q Activity

+1 / −0 / ↑1 / ↓6

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • Contineum Therapeutics, Inc.$884.5K +14.3%
Show all 1

Top Trims

  • Lenz Therapeutics, Inc.-$18.2M -42.8%
  • Monte Rosa Therapeutics, Inc.-$16.4M -23.9%
  • Jade Biosciences, Inc.-$2.1M -8.9%
  • CRISPR Therapeutics AG-$724.8K -9.3%
  • Tempest Therapeutics, Inc.-$331.8K -42.9%
Show all 6

New Positions

  • Century Therapeutics, Inc.$27.5M
Show all 1

Exited Positions

  • No exits this quarter.
Show all 0
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Monte Rosa Therapeutics, Inc. GLUE 61225M102 $52.3M 37.00% 3,180,780 SH
2 Century Therapeutics, Inc. IPSC 15673T100 $27.5M 19.44% 12,166,109 SH
3 Lenz Therapeutics, Inc. LENZ 52635N103 $24.3M 17.19% 2,656,888 SH
4 Jade Biosciences, Inc. JBIO 008064206 $21.4M 15.16% 1,525,820 SH
5 Contineum Therapeutics, Inc. CTNM 21217B100 $7.1M 5.01% 542,628 SH
6 CRISPR Therapeutics AG CRSP H17182108 $7.1M 5.01% 148,831 SH
7 Skye Bioscience, Inc. SKYE 83086J200 $1.2M 0.87% 2,007,704 SH
8 Tempest Therapeutics, Inc. TPST 87978U108 $442.4K 0.31% 269,772 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-05 $141.4M 8 0001193125-26-206555
2025-12-31 2026-02-12 $151.1M 7 0001193125-26-048719